Diabetic Complications is an indication for drug development with over 50 pipeline drugs currently active. According to GlobalData, preregistered drugs for Diabetic Complications have a 50% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Diabetic Complications compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Diabetic Complications overview
Diabetes is a chronic autoimmune disease if untreated or in severe illness leads to complications of the kidney, lungs, heart, and other major organs. Complications are acute and chronic. Hypoglycemia and ketoacidosis are acute complications. Diabetic Retinopathy, diabetic nephropathy, diabetic neuropathy, and other problems in feet (ulcers), hearing, and mental health are chronic. These complications occur in both type-1 and type-2. A sudden drop in blood glucose levels causes hypoglycemia while the production of ketone bodies in the absence of insulin causes ketoacidosis. Ketoacidosis is a common complication in type-1 DM. Cataracts and glaucoma are common retinal complications. Excess sugar in neurons causes diabetic nephropathy. Sodium bicarbonate is the primary treatment approach in ketoacidosis to decrease the acidity while symptomatic management with IV fluids, antibiotics in other complications.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Diabetic Complications, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
